Sametec Airmaster

Sametec Airmaster is indicated in adults and adolescents 12 years of age and older. Sametec Airmaster is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate for example in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or in patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. Sametec Airmaster is indicated for the symptomatic treatment of patients with COPD, with a FEV1 < 60 % predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.